Comprehensive Stock Comparison
Compare OS Therapies Incorporated (OSTX) vs Merus N.V. (MRUS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | OSTX | Beta 0.81 vs MRUS's 0.90 |
| Dividends | OSTX | 100.0% yield; 1-year raise streak; MRUS pays no meaningful dividend |
| Momentum (1Y) | MRUS | +91.1% vs OSTX's -10.9% |
| Efficiency (ROA) | MRUS | -43.4% ROA vs OSTX's -204.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
OS Therapies is a clinical-stage biopharmaceutical company developing novel treatments for osteosarcoma and other solid tumors. It aims to generate revenue through future drug sales and potential licensing deals — primarily from its lead candidate OST-HER2 (an off-the-shelf immunotherapy) and its tunable antibody-drug conjugate platform. The company's competitive advantage lies in its specialized focus on osteosarcoma — a rare pediatric cancer with limited treatment options — and its proprietary plug-and-play ADC technology with pH-sensitive linkers.
Merus N.V. is a clinical-stage biotechnology company developing bispecific antibody therapies for cancer treatment. It generates revenue primarily through research collaborations and licensing deals — with no commercial products yet — while advancing its pipeline through clinical trials. The company's competitive advantage lies in its proprietary antibody discovery platform that enables the creation of novel bispecific antibodies targeting multiple cancer pathways simultaneously.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MRUS leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
MRUS and OSTX operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $51M |
| EBITDAEarnings before interest/tax | -$19M | -$329M |
| Net IncomeAfter-tax profit | -$18M | -$335M |
| Free Cash FlowCash after capex | -$13M | -$318M |
| Gross MarginGross profit ÷ Revenue | — | -2.2% |
| Operating MarginEBIT ÷ Revenue | — | -6.5% |
| Net MarginNet income ÷ Revenue | — | -6.5% |
| FCF MarginFCF ÷ Revenue | — | -6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.7% | +13.7% |
Valuation Metrics
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| Market CapShares × price | $49M | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $43M | $6.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.83x | -26.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 195.71x |
| Price / BookPrice ÷ Book value/share | 37.81x | 8.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MRUS delivers a -50.6% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-4 for OSTX. On the Piotroski fundamental quality scale (0–9), MRUS scores 4/9 vs OSTX's 3/9, reflecting mixed financial health.
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | -50.6% |
| ROA (TTM)Return on assets | -2.0% | -43.4% |
| ROICReturn on invested capital | — | -74.6% |
| ROCEReturn on capital employed | -7.5% | -48.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$6M | -$283M |
| Cash & Equiv.Liquid assets | $6M | $293M |
| Total DebtShort + long-term debt | $0 | $10M |
| Interest CoverageEBIT ÷ Interest expense | -2418.83x | — |
Total Returns (with DRIP)
A $10,000 investment in MRUS five years ago would be worth $37,768 today (with dividends reinvested), compared to $5,857 for OSTX. Over the past 12 months, MRUS leads with a +91.1% total return vs OSTX's -10.9%. The 3-year compound annual growth rate (CAGR) favors MRUS at 67.7% vs OSTX's -16.3% — a key indicator of consistent wealth creation.
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| YTD ReturnYear-to-date | +9.7% | 0.0% |
| 1-Year ReturnPast 12 months | -10.9% | +91.1% |
| 3-Year ReturnCumulative with dividends | -41.4% | +371.9% |
| 5-Year ReturnCumulative with dividends | -41.4% | +277.7% |
| 10-Year ReturnCumulative with dividends | -41.4% | +796.4% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +67.7% |
Risk & Volatility
OSTX is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than MRUS's 0.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRUS currently trades 92.6% from its 52-week high vs OSTX's 57.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.90x |
| 52-Week HighHighest price in past year | $2.57 | $97.14 |
| 52-Week LowLowest price in past year | $1.12 | $33.19 |
| % of 52W HighCurrent price vs 52-week peak | +57.2% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 14.9 |
| Avg Volume (50D)Average daily shares traded | 510K | 520K |
Analyst Outlook
OSTX is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | OSTXOS Therapies Inco… | MRUSMerus N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $97.00 |
| # AnalystsCovering analysts | — | 22 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $1.50 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 24 | Feb 26 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | 100 | 55.38 | -44.6% |
| Merus N.V. (MRUS) | 100 | 171.69 | +71.7% |
Merus N.V. (MRUS) returned +278% over 5 years vs OS Therapies Incorp… (OSTX)'s -41%. A $10,000 investment in MRUS 5 years ago would be worth $37,768 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | $0.00 | $0.00 | — |
| Merus N.V. (MRUS) | $2M | $35M | +1730.9% |
Merus N.V.'s revenue grew from $2M (2015) to $35M (2024) — a 38.1% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | -0 | -0.52 | -74185.7% |
| Merus N.V. (MRUS) | -1.65 | -3.35 | -103.0% |
Merus N.V.'s EPS grew from $-1.65 (2015) to $-3.35 (2024).
Chart 4Free Cash Flow — 5 Years
OS Therapies Incorporated generated $-7M FCF in 2024 (-65% vs 2021). Merus N.V. generated $-188M FCF in 2024 (-210% vs 2021).
OSTX vs MRUS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OSTX or MRUS a better buy right now?
Analysts rate Merus N.V. (MRUS) a "Hold" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSTX or MRUS?
Over the past 5 years, Merus N.V. (MRUS) delivered a total return of +277.7%, compared to -41.4% for OS Therapies Incorporated (OSTX). A $10,000 investment in MRUS five years ago would be worth approximately $38K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRUS returned +796.4% versus OSTX's -41.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSTX or MRUS?
By beta (market sensitivity over 5 years), OS Therapies Incorporated (OSTX) is the lower-risk stock at 0.81β versus Merus N.V.'s 0.90β — meaning MRUS is approximately 12% more volatile than OSTX relative to the S&P 500.
04Which has better profit margins — OSTX or MRUS?
OS Therapies Incorporated (OSTX) is the more profitable company, earning 0.0% net margin versus -595.9% for Merus N.V. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OSTX leads at 0.0% versus -753.0% for MRUS. At the gross margin level — before operating expenses — MRUS leads at 37.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OSTX or MRUS?
In this comparison, OSTX (100.0% yield) pays a dividend. MRUS does not pay a meaningful dividend and should not be held primarily for income.
06Is OSTX or MRUS better for a retirement portfolio?
For long-horizon retirement investors, OS Therapies Incorporated (OSTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), 100.0% yield). Both have compounded well over 10 years (OSTX: -41.4%, MRUS: +796.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OSTX and MRUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OSTX is a small-cap income-oriented stock; MRUS is a small-cap quality compounder stock. OSTX pays a dividend while MRUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.